BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Dow
Teva
Accenture
Cantor Fitzgerald
Citi
Colorcon
Chubb
Cipla
McKinsey

Generated: January 21, 2018

DrugPatentWatch Database Preview

Aspirin; omeprazole - Generic Drug Details

« Back to Dashboard

What are the generic sources for aspirin; omeprazole and what is the scope of aspirin; omeprazole freedom to operate?

Aspirin; omeprazole
is the generic ingredient in one branded drug marketed by Aralez Pharms and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Aspirin; omeprazole has forty-five patent family members in twenty-three countries.

There are twenty-one drug master file entries for aspirin; omeprazole. One supplier is listed for this compound.
Summary for aspirin; omeprazole
International Patents:45
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 21
Suppliers / Packagers: 1
Clinical Trials: 1,338
Drug Prices:see low prices
DailyMed Link:aspirin; omeprazole at DailyMed

US Patents and Regulatory Information for aspirin; omeprazole

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aralez Pharms YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-002 Sep 14, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for aspirin; omeprazole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,161,920 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
9,801,824 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Subscribe
8,557,285 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
9,345,695 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
8,852,636 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
9,198,888 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
8,858,996 Pharmaceutical compositions for the coordinated delivery of NSAIDS ➤ Subscribe
9,707,181 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Subscribe
9,220,698 Method for delivering a pharmaceutical composition to patient in need thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for aspirin; omeprazole

Supplementary Protection Certificates for aspirin; omeprazole

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00481 Netherlands ➤ Subscribe PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
1411900/01 Switzerland ➤ Subscribe PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
2012 00036 Denmark ➤ Subscribe
858 Luxembourg ➤ Subscribe 91858, EXPIRES: 20251105
C/GB11/015 United Kingdom ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
90013-1 Sweden ➤ Subscribe PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
11/016 Ireland ➤ Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
5 Finland ➤ Subscribe
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Julphar
Citi
Express Scripts
Cantor Fitzgerald
Johnson and Johnson
Medtronic
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot